Net margin is calculated as Net Income divided by its Revenue. Tanvex BioPharma's Net Income for the
three
months ended in Dec. 2025 was NT$-420.5 Mil. Tanvex BioPharma's Revenue for the
three
months ended in Dec. 2025 was NT$179.0 Mil. Therefore, Tanvex BioPharma's net margin for the quarter that ended in Dec. 2025 was -235.00%.
The historical rank and industry rank for Tanvex BioPharma's Net Margin % or its related term are showing as below:
TPE:6541'
s Net Margin % Range Over the Past 10 Years
Min: -701412 Med: -5654.56 Max: -374.13
Current: -374.13
TPE:6541's Net Margin % is ranked worse than 68.09% of 940
companies
in the Biotechnology industry
Industry Median: -88.295
vs TPE:6541: -374.13
Tanvex BioPharma (TPE:6541) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Tanvex BioPharma Net Margin % Related Terms
Tanvex BioPharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6541 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Tanvex BioPharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma (TPE:6541) has a Net Margin % of -235.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Tanvex BioPharma and its competitors. According to the industry distribution chart, Tanvex BioPharma ranks #640 out of 940 companies in the Biotechnology industry, placing it in the top 68.1%.
Is Tanvex BioPharma's Net Margin % too high?
Tanvex BioPharma's current Net Margin % is -235.00%. Based on the distribution chart, Tanvex BioPharma ranks #640 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #640 out of 940 companies for Net Margin %. This places Tanvex BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current Net Margin % is -235.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current Net Margin % is -235.00%. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Net Margin % is -235.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?
Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued.
The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61.
GuruFocus considers Tanvex BioPharma to be Possible Value Trap.
Key valuation signals for TPE:6541:
Net Margin %: -235.00%
GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score
Get the complete analysis for TPE:6541
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
